Sunitinib Malate Capsule
Product Images NDC 72205-118

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sunitinib Malate (NDC 72205-118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sunitinib-capsules-12-5mg-cntr-label (Sunitinib Capsules 12 5mg Cntr Label)

Label for Sunitinib Malate Capsules, 12.5 mg strength, oral dosage form. The label states Rx Only and the NDC number 72205-116-28. It includes storage instructions, manufacturer information (MSN Laboratories Private Limited, India), and distributor details (Novadoz Pharmaceuticals LLC, Piscataway, NJ). The package contains 28 capsules. The label also instructs pharmacists to provide the Medication Guide with the product.*

FDA Label Image

Sunitinib-capsules-25mg-cntr-label. (Sunitinib Capsules 25mg Cntr Label)

Sunitinib Malate Capsules 25 mg oral dosage label showing the prescription status, quantity of 28 capsules, and labeler Novadoz Pharmaceuticals LLC. It includes storage instructions, manufacturer information (MSN Laboratories, India), and a note for pharmacists to dispense the medication guide. The label features multiple barcodes and a distinctive blue highlight on the strength.*

FDA Label Image

Sunitinib-capsules-37-5mg-cntr-label (Sunitinib Capsules 37 5mg Cntr Label)

Label of Sunitinib Malate Capsules 37.5 mg, an oral prescription drug. The label shows the dosage strength as 37.5 mg, quantity as 28 capsules, and includes storage instructions. It is manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC. The label includes the NDC 72205-118-28 and barcode information.*

FDA Label Image

Sunitinib-capsules-50mg-cntr-label (Sunitinib Capsules 50mg Cntr Label)

Label for Sunitinib Malate Capsules 50 mg, oral dosage form in a package of 28 capsules. The label includes storage instructions, manufacturer and distributor details, and a notice to pharmacists to dispense the accompanying Medication Guide. Manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC.*

FDA Label Image

Sunitinib-figure-1 (Sunitinib Figure 1)

A Kaplan-Meier survival curve graph showing time to tumor progression probability (%) over time in weeks for Sunitinib Malate versus placebo. The black line represents Sunitinib Malate with a median progression time of 27.3 weeks, while the gray line represents placebo with a median of 6.4 weeks. The graph includes hazard ratio and confidence interval data.*

FDA Label Image

Sunitinib-figure-2 (Sunitinib Figure 2)

A Kaplan-Meier progression-free survival curve comparing Sunitinib Malate and IFN-alpha treatments, showing probability of progression-free survival over 60 weeks. The chart includes a survival probability y-axis (%) and time x-axis (weeks). It presents median survival weeks, hazard ratio, confidence interval, and number of subjects at risk over time for each treatment group.*

FDA Label Image

Sunitinib-figure-3 (Sunitinib Figure 3)

A Kaplan-Meier survival curve chart showing disease-free survival probability over time in years. The chart compares two groups: Sunitinib Malate (N=309) with a median disease-free survival of 6.8 years and Placebo (N=306) with a median of 5.6 years. The graph includes hazard ratio (0.76), 95% confidence interval (0.59, 0.98), and p-value (0.03). The number of subjects at risk is displayed below the time axis for both groups at multiple time points up to 8 years.*

FDA Label Image

Sunitinib-figure-4 (Sunitinib Figure 4)

A Kaplan-Meier curve illustrating progression-free survival probability over time (months) comparing Sunitinib Malate and placebo groups. The graph shows higher survival probability in the Sunitinib Malate group with a median of 10.2 months versus 5.4 months for placebo. It includes hazard ratio, confidence interval, and p-value, with number of subjects at risk listed below the time axis.*

FDA Label Image

Sunitinib-structure (Sunitinib Structure)

Chemical structure of Sunitinib Malate, showing the molecular composition and arrangement of the active ingredient Sunitinib Malate used in oral capsule form by Novadoz Pharmaceuticals LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.